TQB-3454 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase III drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how TQB-3454’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TQB-3454 overview
TQB-3454 is under development for the treatment of metastatic solid tumors, hematological tumors, refractory and relapsed acute myeloid leukemia (AML), advanced biliary carcinoma, astrocytoma and myelodysplastic syndrome (MDS). The drug candidate is administered by oral route as tablet. It acts by targeting isocitrate dehydrogenase 1 (IDH1).
Chia Tai Tianqing Pharmaceutical Group overview
Chia Tai Tianqing Pharmaceutical Group (CTTQ) subsidiary of Sino Biopharmaceutical Ltd, is a pharmaceutical company that offers integrated R&D, manufacturing, marketing, sales and distribution services. The company manufacture prescription medicines in various core therapeutic areas, including liver diseases, oncology, respiratory diseases, antibiotics and diabetes. CTTQ produces dosage forms such as freeze-dried powder, large and small volume injections, hard capsules, sheet pills, granules, powders, soft capsules, pills, ointments, creams, pastes, gels, transdermal patches and herbal extracts, and others. It conducts research activities in the areas of anti-tumor, and liver disease. The company operates through its technology and research and development centers in Jiangsu. Its APIs and FDFs are sold to all major continents including Americas, Europe, Asia, and Africa. CTTQ is headquartered in Lianyungang, Nanjing, China.
For a complete picture of TQB-3454’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
